Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30000 participants
OBSERVATIONAL
2018-03-19
2025-01-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SCREaning of Advanced Liver Fibrosis Using Non-Invasive Tests in General Population
NCT05880173
Screening for Chronic Liver Diseases in General Population
NCT06366425
Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers
NCT03308916
Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study
NCT01306110
Prospective Evaluation of FibroScan in Patients Treated With Methotrexate
NCT00673101
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to give informed consent
Exclusion Criteria
* Subjects with mental incapacity, language barrier, insufficient social support or any other reason considered by the investigator precluding adequate understanding or cooperation in the study
* Subjects with a history of current malignancy including solid tumors and hematologic disorders
* Subjects with significant extrahepatic disease that may impair short-term prognosis (including congestive heart failure New York Heart Association Grade IV, COPD GOLD \>3)
* Subjects with kidney disease (serum creatinine \>3mg/dL or under renal replacement therapy)
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Judit Pich Martínez
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Judit Pich Martínez
Clinical Research Manager
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pere Ginès, MD
Role: STUDY_CHAIR
Fundacion Clinic per a la Recerca Biomédica
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dubrava Hospital
Zagreb, , Croatia
Poliklinika Croatia
Zagreb, , Croatia
Odense University Hospital
Odense, , Denmark
Centre de santé Municipal Etienne Gatineau-Sailliant de Genevilliers
Gennevilliers, , France
Centre de Recherche Clinique - CRC
Paris, , France
Hospital Avicenne
Paris, , France
Hospital Beaujon
Paris, , France
Homburg Hospital
Homburg, , Germany
Altstadtpraxis
Mainz, , Germany
Mainz Hospital
Mainz, , Germany
Praxis Mombach
Mainz, , Germany
MVZ Dres.Schneider Kaiserslautern
Rodenbach, , Germany
Medicina Di gruppo di montagnana
Padua, , Italy
Vigonza Medica
Padua, , Italy
Medical Center Rotterdam
Rotterdam, , Netherlands
F. D. Roosevelt Univ. Hospital
Banská Bystrica, , Slovakia
Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
SEAT
Martorell, Barcelona, Spain
CAP II El Maresme
Mataró, Barcelona, Spain
CAP II Santa Coloma de Gramanet
Santa Coloma de Gramenet, Barcelona, Spain
CAP La Florida
Santa Perpètua de Mogoda, Barcelona, Spain
CAP Barceloneta
Barcelona, , Spain
Hospital del Mar
Barcelona, , Spain
CAP Bordeta-Magòria
Barcelona, , Spain
CAP Río de Janeiro
Barcelona, , Spain
CAP Ciutat Meridiana
Barcelona, , Spain
CAP Sant Rafael
Barcelona, , Spain
Hospital Universirati Vall d'Hebrón
Barcelona, , Spain
Hospital Clínic de Barcelona
Barcelona, , Spain
CAP Adrià
Barcelona, , Spain
CAP Besos
Barcelona, , Spain
CAP La Marina
Barcelona, , Spain
CAP Numància
Barcelona, , Spain
CAP Vila de Gracia
Barcelona, , Spain
CAP Vila Olimpica
Barcelona, , Spain
Hospital Gregorio Marañon
Madrid, , Spain
CAP La Llantia
Mataró, , Spain
Oak Lodge Medical Centre
Edgware, , United Kingdom
Royal Free Hospital
London, , United Kingdom
James Wigg
London, , United Kingdom
Mild May
London, , United Kingdom
Oakleigh park
London, , United Kingdom
St Andrews Medical Practice
London, , United Kingdom
Nottingham University Hospital
Nottingham, , United Kingdom
King's Mill Hospital
Sutton in Ashfield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Graupera I, Thiele M, Ma AT, Serra-Burriel M, Pich J, Fabrellas N, Caballeria L, de Knegt RJ, Grgurevic I, Reichert M, Roulot D, Schattenberg JM, Pericas JM, Angeli P, Tsochatzis EA, Guha IN, Garcia-Retortillo M, Morillas RM, Hernandez R, Hoyo J, Fuentes M, Madir A, Juanola A, Soria A, Juan M, Carol M, Diaz A, Detlefsen S, Toran P, Pera G, Fournier C, Llorca A, Newsome PN, Manns M, de Koning HJ, Serra-Burriel F, Cucchietti F, Arslanow A, Korenjak M, van Kleef L, Falco JL, Kamath PS, Karlsen TH, Castera L, Lammert F, Krag A, Gines P; LiverScreen Consortium investigators. LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries. BMC Public Health. 2022 Jul 19;22(1):1385. doi: 10.1186/s12889-022-13724-6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LiverScreen
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.